Document:

<PAGE>   1
                                                                    Exhibit 10.1

                               GMP COMPANIES, INC.
                   1999 AMENDED AND RESTATED STOCK OPTION PLAN
                        Adopted by Board on June 19, 2000

         1.       ESTABLISHMENT, PURPOSE AND TERM OF PLAN.

                  1.1      ESTABLISHMENT. The GMP Companies, Inc. 1999 Stock
Option Plan (the "PLAN") was established effective as of June 17, 1999 (the
"EFFECTIVE DATE").

                  1.2      PURPOSE. The purpose of the Plan is to advance the
interests of the Participating Company Group and its stockholders by providing
an incentive to attract, retain and reward persons performing services for the
Participating Company Group and by motivating such persons to contribute to the
growth and profitability of the Participating Company Group.

                  1.3      TERM OF PLAN. The Plan shall continue in effect until
the earlier of its termination by the Board or the date on which all of the
shares of Stock available for issuance under the Plan have been issued and all
restrictions on such shares under the terms of the Plan and the agreements
evidencing Options granted under the Plan have lapsed. However, all Incentive
Stock Options shall be granted, if at all, within ten (10) years from the
Effective Date.

         2.       DEFINITIONS AND CONSTRUCTION.

                  2.1      DEFINITIONS. Whenever used herein, the following
terms shall have their respective meanings set forth below:

                           (a)      "BOARD" means the Board of Directors of the
Company.

                           (b)      "CODE" means the Internal Revenue Code of
1986, as amended, and any applicable regulations promulgated thereunder.

                           (c)      "COMMITTEE" means the Compensation Committee
or other committee of the Board duly appointed to administer the Plan and having
such powers as shall be specified by the Board, or if no such committee is
appointed, the Board.

                           (d)      "COMPANY" means GMP Companies, Inc., a
Delaware corporation, or any successor corporation thereto.

                           (e)      "CONSULTANT" means any person, including an
advisor, engaged by a Participating Company to render services other than as an
Employee or a Director.

                           (f)      "DIRECTOR" means a member of the Board or of
the board of directors of any other Participating Company.

                           (g)      "DISABILITY" means the inability of the
Optionee, in the opinion of a qualified physician acceptable to the Company, to
perform the major duties of the Optionee's position with the Participating
Company Group because of the sickness or injury of the Optionee.

<PAGE>   2

                           (h)      "EMPLOYEE" means any person treated as an
employee (including an officer or a Director who is also treated as an employee)
in the records of a Participating Company and, with respect to any Incentive
Stock Option granted to such person, who is an employee for purposes of Section
422 of the Code; provided, however, that neither service as a Director nor
payment of a director's fee shall be sufficient to constitute employment for
purposes of the Plan.

                           (i)      "EXCHANGE ACT" means the Securities Exchange
Act of 1934, as amended.

                           (j)      "FAIR MARKET VALUE" means, as of any date,
the value of a share of Stock or other property as determined by the Committee,
in its sole discretion, subject to the following:

                                    (i)      If, on such date, there is a public
market for the Stock, the Fair Market Value of a share of Stock shall be the
closing sale price of a share of Stock (or the mean of the closing bid and asked
prices of a share of Stock if the Stock is so quoted instead) as quoted on the
Nasdaq National Market, The Nasdaq Small-Cap Market or such other national or
regional securities exchange or market system constituting the primary market
for the Stock, as reported in The Wall Street Journal or such other source as
the Committee deems reliable. If the relevant date does not fall on a day on
which the Stock has traded on such securities exchange or market system, the
date on which the Fair Market Value shall be established shall be the last day
on which the Stock was so traded prior to the relevant date, or such other
appropriate day as shall be determined by the Committee, in its sole discretion.

                                    (ii)     If, on such date, there is no
public market for the Stock, the Fair Market Value of a share of Stock shall be
as determined by the Committee without regard to any restriction other than a
restriction which, by its terms, will never lapse.

                           (k)      "GRANT AGREEMENT" means the Stock Option
Grant Agreement attached as Exhibit A to the Option Agreement and made a part
thereof.

                           (l)      "INCENTIVE STOCK OPTION" means an Option
intended to be (as set forth in the Option Agreement) and which qualifies as an
incentive stock option within the meaning of Section 422(b) of the Code.

                           (m)      "INSIDER" means an officer or a Director of
the Company or any other person whose transactions in Stock are subject to
Section 16 of the Exchange Act.

                           (n)      "NONSTATUTORY STOCK OPTION" means an Option
not intended to be (as set forth in the Option Agreement) or which does not
qualify as an Incentive Stock Option.

                           (o)      "OPTION" means a right to purchase Stock
pursuant to the terms and conditions of the Plan. An Option may be either an
Incentive Stock Option or a Nonstatutory Stock Option.

                                       2
<PAGE>   3

                           (p)      "OPTION AGREEMENT" means a written
agreement(s) between the Company and an Optionee setting forth the terms,
conditions and restrictions of the Option granted to the Optionee and any shares
of Stock acquired upon the exercise thereof. The Option Agreement shall include
the Stock Option Grant Agreement attached as an Exhibit thereto.

                           (q)      "OPTIONEE" means a person who has been
granted one or more Options.

                           (r)      "PARENT CORPORATION" means any present or
future "parent corporation" of the Company, as defined in Section 424(e) of the
Code.

                           (s)      "PARTICIPATING COMPANY" means the Company or
any Parent Corporation or Subsidiary Corporation.

                           (t)      "PARTICIPATING COMPANY GROUP" means, at any
point in time, all corporations collectively which are then Participating
Companies.

                           (u)      "RULE 16B-3" means Rule 16b-3 under the
Exchange Act, as amended from time to time, or any successor rule or regulation.

                           (v)      "SECTION 162(M)" means Section 162(m) of the
Code, as amended by the Revenue Reconciliation Act of 1993 (P.L. 103-66).

                           (w)      "SECURITIES ACT" means the Securities Act of
1933, as amended.

                           (x)      "SERVICE" means an Optionee's employment or
service with the Participating Company Group, whether in the capacity of an
Employee, a Director or a Consultant. The Optionee's Service shall not be deemed
to have terminated merely because of a change in the capacity in which the
Optionee renders Service to the Participating Company Group or a change in the
Participating Company for which the Optionee renders such Service, provided that
there is no interruption or termination of the Optionee's Service. Furthermore,
an Optionee's Service with the Participating Company Group shall not be deemed
to have terminated if the Optionee takes any military leave, sick leave, or
other bona fide leave of absence approved by the Company; provided, however,
that if any such leave exceeds ninety (90) days, on the ninety-first (91st) day
of such leave the Optionee's Service shall be deemed to have terminated unless
the Optionee's right to return to Service with the Participating Company Group
is guaranteed by statute or contract. Notwithstanding the foregoing, unless
otherwise designated by the Committee or required by law, a leave of absence
shall not be treated as Service for purposes of determining vesting under the
Optionee's Option Agreement. The Optionee's Service shall be deemed to have
terminated either upon an actual termination of Service or upon the corporation
for which the Optionee performs Service ceasing to be a Participating Company.
Subject to the foregoing, the Committee, in its sole discretion, shall determine
whether the Optionee's Service has terminated and the effective date of such
termination.

                           (y)      "STOCK" means the common stock of the
Company, as adjusted from time to time in accordance with Section 4.2.

                                       3
<PAGE>   4

                           (z)      "SUBSIDIARY CORPORATION" means any present
or future "subsidiary corporation" of the Company, as defined in Section 424(f)
of the Code.

                           (aa)     "TEN PERCENT OWNER OPTIONEE" means an
Optionee who, at the time an Option is granted to the Optionee, owns stock
possessing more than ten percent (10%) of the total combined voting power of all
classes of stock of a Participating Company within the meaning of Section
422(b)(6) of the Code.

                  2.2      CONSTRUCTION. Captions and titles contained herein
are for convenience only and shall not affect the meaning or interpretation of
any provision of the Plan. Except when otherwise indicated by the context, the
singular shall include the plural and the plural shall include the singular. Use
of the term "or" is not intended to be exclusive, unless the context clearly
requires otherwise.

         3.       ADMINISTRATION.

                  3.1      ADMINISTRATION BY THE COMMITTEE. The Plan shall be
administered by the Committee. All questions of interpretation of the Plan or of
any Option shall be determined by the Committee, and such determinations shall
be final and binding upon all persons having an interest in the Plan or such
Option. Any officer of a Participating Company shall have the authority to act
on behalf of the Company with respect to any matter, right, obligation,
determination or election which is the responsibility of or which is allocated
to the Company herein, provided the officer has apparent authority with respect
to such matter, right, obligation, determination or election.

                  3.2      ADMINISTRATION WITH RESPECT TO INSIDERS. With respect
to participation by Insiders in the Plan, at any time that any class of equity
security of the Company is registered pursuant to Section 12 of the Exchange
Act, the Plan shall be administered in compliance with the requirements, if any,
of Rule 16b-3.

                  3.3      POWERS OF THE COMMITTEE. In addition to any other
powers set forth in the Plan and subject to the provisions of the Plan, the
Committee shall have the full and final power and authority, in its sole
discretion:

                           (a)      to determine the persons to whom, and the
time or times at which, Options shall be granted and the number of shares of
Stock to be subject to each Option;

                           (b)      to designate Options as Incentive Stock
Options or Nonstatutory Stock Options;

                           (c)      to determine the Fair Market Value of shares
of Stock or other property;

                           (d)      to determine the terms, conditions and
restrictions applicable to each Option (which need not be identical) and any
shares acquired upon the exercise thereof, including, without limitation, (i)
the exercise price of the Option, (ii) the method of payment for shares
purchased upon the exercise of the Option, (iii) the method for satisfaction of
any tax

                                       4
<PAGE>   5

withholding obligation arising in connection with the Option or such shares,
including by the withholding or delivery of shares of Stock, (iv) the timing,
terms and conditions of the exercisability of the Option or the vesting of any
shares of Stock acquired upon the exercise thereof, (v) the time of the
expiration of the Option, (vi) the effect of the Optionee's termination of
Service with the Participating Company Group on any of the foregoing, and (vii)
all other terms, conditions and restrictions applicable to the Option or such
shares not inconsistent with the terms of the Plan;

                           (e)      to approve one or more forms of Option
Agreement;

                           (f)      to amend, modify, extend, cancel, renew,
reprice or otherwise adjust the exercise price of, or grant a new Option in
substitution for, any Option or to waive any restrictions or conditions
applicable to any Option or any shares acquired upon the exercise thereof;

                           (g)      to accelerate, continue, extend or defer the
exercisability of any Option or the vesting of any shares acquired upon the
exercise thereof, including with respect to the period following an Optionee's
termination of Service with the Participating Company Group;

                           (h)      to prescribe, amend or rescind rules,
guidelines and policies relating to the Plan, or to adopt supplements to, or
alternative versions of, the Plan, including, without limitation, as the
Committee deems necessary or desirable to comply with the laws of, or to
accommodate the tax policy or custom of, foreign jurisdictions whose citizens
may be granted Options; and

                           (i)      to correct any defect, supply any omission
or reconcile any inconsistency in the Plan or any Option Agreement and to make
all other determinations and take such other actions with respect to the Plan or
any Option as the Committee may deem advisable to the extent consistent with the
Plan and applicable law.

                  3.4      COMMITTEE COMPLYING WITH SECTION 162(M) AND RULE
16B-3. If a Participating Company is a "publicly held corporation" within the
meaning of Section 162(m), the Committee shall be comprised solely of two or
more persons who qualify as "outside directors" within the meaning of Section
162(m) and as "non-employee directors" within the meaning of Rule 16b-3
promulgated under the Exchange Act.

         4.       SHARES SUBJECT TO PLAN.

                  4.1      MAXIMUM NUMBER OF SHARES ISSUABLE. Subject to
adjustment as provided in Section 4.2, the maximum aggregate number of shares of
Stock that may be issued under the Plan shall be Three Million (3,000,000) and
shall consist of authorized but unissued or reacquired shares of Stock or any
combination thereof. If an outstanding Option for any reason expires or is
terminated or canceled or shares of Stock acquired, subject to repurchase, upon
the exercise of an Option are repurchased by the Company, the shares of Stock
allocable to the

                                       5
<PAGE>   6

unexercised portion of such Option, or such repurchased shares of Stock, shall
again be available for issuance under the Plan.

                  4.2      ADJUSTMENTS FOR CHANGES IN CAPITAL STRUCTURE. In the
event of any stock dividend, stock split, reverse stock split, recapitalization,
combination, reclassification or similar change in the capital structure of the
Company, appropriate adjustments shall be made in the number and class of shares
subject to the Plan and to any outstanding Options and in the exercise price per
share of any outstanding Options. If a majority of the shares which are of the
same class as the shares that are subject to outstanding Options are exchanged
for, converted into, or otherwise become (whether or not pursuant to a Change in
Control, as defined in Section 8.1) shares of another corporation (the "NEW
SHARES"), the Committee may unilaterally amend the outstanding Options to
provide that such Options are exercisable for New Shares. In the event of any
such amendment, the number of shares subject to, and the exercise price per
share of, the outstanding Options shall be adjusted in a fair and equitable
manner as determined by the Committee, in its sole discretion. Notwithstanding
the foregoing, any fractional share resulting from an adjustment pursuant to
this Section 4.2 shall be rounded up or down to the nearest whole number, as
determined by the Committee, and in no event may the exercise price of any
Option be decreased to an amount less than the par value, if any, of the stock
subject to the Option. The adjustments determined by the Committee pursuant to
this Section 4.2 shall be final, binding and conclusive.

         5.       ELIGIBILITY AND OPTION LIMITATIONS.

                  5.1      PERSONS ELIGIBLE FOR OPTIONS. Options may be granted
only to Employees, Consultants, and Directors. For purposes of the foregoing
sentence, "EMPLOYEES," "CONSULTANTS" and "DIRECTORS" shall include prospective
Employees, prospective Consultants and prospective Directors to whom Options are
granted in connection with written offers of an employment or other service
relationship with the Participating Company Group. Eligible persons may be
granted more than one (1) Option.

                  5.2      OPTION GRANT RESTRICTIONS. Any person who is not an
Employee on the effective date of the grant of an Option to such person may be
granted only Nonstatutory Stock Options. An Incentive Stock Option granted to a
prospective Employee upon the condition that such person become an Employee
shall be deemed granted effective on the date such person commences Service with
a Participating Company as an Employee, with an exercise price determined as of
such date in accordance with Section 6.1.

                  5.3      FAIR MARKET VALUE LIMITATION. To the extent that
options designated as Incentive Stock Options (granted under all stock option
plans of the Participating Company Group, including the Plan) become exercisable
by an Optionee for the first time during any calendar year for Stock having a
Fair Market Value greater than One Hundred Thousand Dollars ($100,000), the
portion of such options which exceeds such amount shall be treated as
Nonstatutory Stock Options. For purposes of this Section 5.3, options designated
as Incentive Stock Options shall be taken into account in the order in which
they were granted, and the Fair Market Value of stock shall be determined as of
the time the option with respect to such Stock is granted. If the Code is
amended to provide for a different limitation from that set forth in this

                                       6
<PAGE>   7

Section 5.3, such different limitation shall be deemed incorporated herein
effective as of the date and with respect to such Options as required or
permitted by such amendment to the Code. If an Option is treated as an Incentive
Stock Option in part and as a Nonstatutory Stock Option in part by reason of the
limitation set forth in this Section 5.3, the Optionee may designate which
portion of such Option the Optionee is exercising. In the absence of such
designation, the Optionee shall be deemed to have exercised the Incentive Stock
Option portion of the Option first. Separate certificates or other evidence of
ownership representing each such portion shall be issued upon the exercise of
the Option.

         6.       TERMS AND CONDITIONS OF OPTIONS.

                  Options shall be evidenced by Option Agreements specifying the
number of shares of Stock covered thereby, in such form as the Committee shall
from time to time establish. No Option or purported Option shall be a valid and
binding obligation of the Company unless evidenced by a fully executed Option
Agreement. Option Agreements may incorporate all or any of the terms of the Plan
by reference and shall comply with and be subject to the following terms and
conditions:

                  6.1      EXERCISE PRICE. The exercise price for each Option
shall be established in the sole discretion of the Committee; provided, however,
that (a) the exercise price per share for an Incentive Stock Option shall be not
less than the Fair Market Value of a share of Stock on the effective date of
grant of the Option, (b) the exercise price per share for a Nonstatutory Stock
Option shall be not less than the par value of a share of Stock on the effective
date of grant of the Option, and (c) no Incentive Stock Option granted to a Ten
Percent Owner Optionee shall have an exercise price per share less than one
hundred ten percent (110%) of the Fair Market Value of a share of Stock on the
effective date of grant of the Option. Notwithstanding the foregoing, an Option
(whether an Incentive Stock Option or a Nonstatutory Stock Option) may be
granted with an exercise price lower than the minimum exercise price set forth
above if such Option is granted pursuant to an assumption or substitution for
another option in a manner qualifying under the provisions of Section 424(a) of
the Code.

                  6.2      EXERCISE PERIOD. Options shall be exercisable at such
time or times, or upon such event or events, and subject to such terms,
conditions, performance criteria, and restrictions as shall be determined by the
Committee and set forth in the Option Agreement evidencing such Option;
provided, however, that (a) no Incentive Stock Option shall be exercisable after
the expiration of ten (10) years after the effective date of grant of such
Option, (b) no Incentive Stock Option granted to a Ten Percent Owner Optionee
shall be exercisable after the expiration of five (5) years after the effective
date of grant of such Option and, (c) no Option granted to a prospective
Employee, prospective Consultant or prospective Director may become exercisable
prior to the date on which such person commences Service with a Participating
Company. Subject to the foregoing, unless otherwise specified by the Committee
in the grant of an Option, any Option granted hereunder shall have a term of ten
(10) years from the Effective Date of grant of the Option.

                                       7
<PAGE>   8
                  6.3      PAYMENT OF EXERCISE PRICE.

                           (a)      FORMS OF CONSIDERATION AUTHORIZED. Except as
otherwise provided below, payment of the exercise price for the number of shares
of Stock being purchased pursuant to any Option shall be in such forms as shall
be permitted by the Committee, which forms may in the discretion of the
Committee include: (i) cash, check, or cash equivalent, (ii) tender to the
Company of shares of Stock owned by the Optionee having a Fair Market Value as
of the date on which the Option is exercised of not less than the exercise
price, (iii) the assignment of the proceeds of a sale or loan with respect to
some or all of the shares being acquired upon the exercise of the Option
(including, without limitation, through an exercise complying with the
provisions of Regulation T as promulgated from time to time by the Board of
Governors of the Federal Reserve System) (a "CASHLESS EXERCISE"), (iv) the
Optionee's promissory note in a form approved by the Committee, (v) such other
consideration as may be approved by the Committee from time to time to the
extent permitted by applicable law, or (vi) any combination thereof.

                           (b)      TENDER OF STOCK. Notwithstanding the
foregoing, an Option may not be exercised by tender to the Company of shares of
Stock to the extent such tender of Stock would constitute a violation of the
provisions of any law, regulation or agreement restricting the redemption of the
Company's stock. Unless otherwise provided by the Committee, an Option may not
be exercised by tender to the Company of shares of Stock unless such shares
either have been owned by the Optionee for more than six (6) months or were not
acquired, directly or indirectly, from the Company.

                           (c)      CASHLESS EXERCISE. The Company reserves, at
any and all times, the right, in the Company's sole and absolute discretion, to
establish, decline to approve or terminate any program or procedures for the
exercise of Options by means of a Cashless Exercise.

                           (d)      PAYMENT BY PROMISSORY NOTE. No promissory
note shall be permitted if the exercise of an Option using a promissory note
would be a violation of any law. Any permitted promissory note shall be on such
terms as the Committee shall determine at the time the Option is granted. The
Committee shall have the authority to permit or require the Optionee to secure
any promissory note used to exercise an Option with the shares of Stock acquired
upon the exercise of the Option or with other collateral acceptable to the
Committee. Unless otherwise provided by the Committee, if the Company at any
time is subject to the regulations promulgated by the Board of Governors of the
Federal Reserve System or any other governmental entity affecting the extension
of credit in connection with the Company's securities, any promissory note shall
comply with such applicable regulations, and the Optionee shall pay the unpaid
principal and accrued interest, if any, to the extent necessary to comply with
such applicable regulations.

                  6.4      TAX WITHHOLDING. The Company shall have the right,
but not the obligation, to deduct from the shares of Stock issuable upon the
exercise of an Option, or to accept from the Optionee the tender of, a number of
whole shares of Stock having a Fair Market Value, as determined by the Company,
equal to all or any part of the federal, state, local and foreign taxes, if any,
required by law to be withheld by the Participating Company Group with respect
to such Option or the shares acquired upon the exercise thereof. Alternatively
or in

                                       8
<PAGE>   9

addition, in its sole discretion, the Company shall have the right to require
the Optionee, through payroll withholding, cash payment or otherwise, including
by means of a Cashless Exercise, to make adequate provision for any such tax
withholding obligations of the Participating Company Group arising in connection
with the Option or the shares acquired upon the exercise thereof. The Company
shall have no obligation to deliver shares of Stock or to release shares of
Stock from an escrow established pursuant to the Option Agreement until the
Participating Company Group's tax withholding obligations have been satisfied by
the Optionee.

                  6.5      REPURCHASE RIGHTS. Shares issued under the Plan may
be subject to a right of first refusal, one or more repurchase options, or other
conditions and restrictions as determined by the Committee in its sole
discretion at the time the Option is granted. The Company shall have the right
to assign at any time any repurchase right it may have, whether or not such
right is then exercisable, to one or more persons as may be selected by the
Company. Upon request by the Committee, each Optionee shall execute any
agreement evidencing such transfer restrictions prior to the receipt of shares
of Stock hereunder and shall promptly present to the Company any and all
certificates representing shares of Stock acquired hereunder for the placement
on such certificates of appropriate legends evidencing any such transfer
restrictions.

                  6.6      EFFECT OF TERMINATION OF SERVICE.

                           (a)      OPTION EXERCISABILITY. Subject to earlier
termination of the Option as otherwise provided herein, an Option shall be
exercisable after an Optionee's termination of Service as follows:

                                    (i)      DISABILITY. If the Optionee's
Service with the Participating Company Group is terminated because of the
Disability of the Optionee, the Option, to the extent unexercised and
exercisable on the date on which the Optionee's Service terminated, may be
exercised by the Optionee (or the Optionee's guardian or legal representative)
at any time prior to the expiration of twelve (12) months (or such longer or
shorter period of time as determined by the Committee, in its sole discretion)
after the date on which the Optionee's Service terminated, but in any event no
later than the date of expiration of the Option's term as set forth in the
Option Agreement evidencing such Option (the "OPTION EXPIRATION DATE").

                                    (ii)     DEATH. If the Optionee's Service
with the Participating Company Group is terminated because of the death of the
Optionee, the Option, to the extent unexercised and exercisable on the date on
which the Optionee's Service terminated, may be exercised by the Optionee's
legal representative or other person who acquired the right to exercise the
Option by reason of the Optionee's death at any time prior to the expiration of
twelve (12) months (or such longer or shorter period of time as determined by
the Committee, in its sole discretion) after the date on which the Optionee's
Service terminated, but in any event no later than the Option Expiration Date.
The Optionee's Service shall be deemed to have terminated on account of death if
the Optionee dies within three (3) months after the Optionee's termination of
Service.

                                    (iii)    OTHER TERMINATION OF SERVICE.
Except as provided in any Option Agreement, if the Optionee's Service with the
Participating Company Group terminates

                                       9
<PAGE>   10

for any reason, except Disability or death, the Option, to the extent
unexercised and exercisable by the Optionee on the date on which the Optionee's
Service terminated, may be exercised by the Optionee within three (3) months (or
such longer or shorter period of time as determined by the Committee, in its
sole discretion) after the date on which the Optionee's Service terminated, but
in any event no later than the Option Expiration Date.

                           (b)      EXTENSION IF EXERCISE PREVENTED BY LAW.
Notwithstanding the foregoing, if the exercise of an Option within the
applicable time periods set forth in Section 6.6(a) is prevented by the
provisions of Section 11 below, the Option shall remain exercisable until one
(1) month after the date the Optionee is notified by the Company that the Option
is exercisable, but in any event no later than the Option Expiration Date.

                           (c)      EXTENSION IF OPTIONEE SUBJECT TO SECTION
16(B). Notwithstanding the foregoing, if a sale within the applicable time
periods set forth in Section 6.6(a) of shares acquired upon the exercise of the
Option would subject the Optionee to suit under Section 16(b) of the Exchange
Act, the Option shall remain exercisable until the earliest to occur of (i) the
tenth (10th) day following the date on which a sale of such shares by the
Optionee would no longer be subject to such suit, (ii) the one hundred and
ninetieth (190th) day after the Optionee's termination of Service, or (iii) the
Option Expiration Date.

         7.       STANDARD FORMS OF OPTION AGREEMENT.

                  7.1      GENERAL. Unless otherwise provided by the Committee
at the time the Option is granted, an Option shall comply with and be subject to
the terms and conditions set forth in the standard form of Option Agreement
adopted by the Committee concurrently with its adoption of the Plan and as
amended from time to time.

                  7.2      AUTHORITY TO VARY TERMS. The Committee shall have the
authority from time to time to vary the terms of any of the standard forms of
Option Agreement described in this Section 7 either in connection with the grant
or amendment of an individual Option or in connection with the authorization of
a new standard form or forms; provided, however, that the terms and conditions
of any such new, revised or amended standard form or forms of Option Agreement
are not inconsistent with the terms of the Plan.

         8.       CHANGE IN CONTROL.

                  8.1      DEFINITIONS.

                           A "CHANGE IN CONTROL" shall be deemed to have
occurred if any of the following occurs with respect to the Company:

                           (a)      Approval by the stockholders of the Company
of a reorganization, merger, consolidation or other form of corporate
transaction or series of transactions, in each case, with respect to which
persons who were the stockholders of the Company immediately prior to such
reorganization, merger or consolidation or other transaction do not, immediately
thereafter, own more than 50% of the combined voting power entitled to vote
generally in the election of directors of the reorganized, merged or
consolidated company's then outstanding

                                       10
<PAGE>   11

voting securities, in substantially the same proportions as their ownership
immediately prior to such reorganization, merger, consolidation or other
transaction, or a liquidation or dissolution of the Company or the sale of all
or substantially all of the assets of the Company (unless such reorganization,
merger, consolidation or other corporate transaction, liquidation, dissolution
or sale is subsequently abandoned); or

                           (b)      Individuals who, as of the date on which the
Option is granted, hereof, constitute the Board (the "Incumbent Board") cease
for any reason to constitute at least a majority of the Board, provided that any
person becoming a director subsequent to the date on which the Option was
granted whose election, or nomination for election by the Company's
stockholders, was approved by a vote of at least a majority of the directors
then comprising the Incumbent Board (other than an election or nomination of an
individual whose initial assumption of office is in connection with an actual or
threatened election contest relating to the election of the Directors of the
Company, as such terms are used in Rule 14a-11 of Regulation 14A promulgated
under the Exchange Act or a successor provision applicable thereto) shall be,
for purposes of this Agreement, considered as though such person were a member
of the Incumbent Board; or

                           (c)      The acquisition (other than from the
Company) by any person, entity or "group," within the meaning of Section
13(d)(3) or 14(d)(2) of the Exchange Act, of beneficial ownership (within the
meaning of Rule 13-d promulgated under the Exchange Act) of more than 50% of
either the then outstanding shares of the Company's Stock or the combined voting
power of the Company's then outstanding voting securities entitled to vote
generally in the election of directors (hereinafter referred to as the ownership
of a "Controlling Interest") excluding, for this purpose, any acquisitions by
(1) the Company or its Subsidiary Corporations, (2) any person, entity or
"group" that as of the date on which the Option is granted owns beneficial
ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act)
of a Controlling Interest or (3) any employee benefit plan of the Company or its
Subsidiary Corporations.

                  8.2      EFFECT OF CHANGE IN CONTROL ON OPTIONS. In the event
of a Change in Control, the surviving, continuing, successor, or purchasing
corporation or parent corporation thereof, as the case may be (the "ACQUIRING
CORPORATION"), shall either assume the Company's rights and obligations under
outstanding Options or substitute for outstanding Options substantially
equivalent options for the Acquiring Corporation's stock. For purposes of this
Section 8.2, an Option shall be deemed assumed if, following the Change in
Control, the Option confers the right to purchase in accordance with its terms
and conditions, for each share of Stock subject to the Option immediately prior
to the Change in Control, the consideration (whether stock, cash or other
securities or property) to which a holder of a share of Stock on the effective
date of the Change in Control was entitled. Notwithstanding the foregoing,
shares acquired upon exercise of an Option prior to the Change in Control and
any consideration received pursuant to the Change in Control with respect to
such shares shall continue to be subject to all applicable provisions of the
Option Agreement evidencing such Option except as otherwise provided in such
Option Agreement. Furthermore, notwithstanding the foregoing, if the corporation
the stock of which is subject to the outstanding Options immediately prior to a
Change in Control described in Section 8.1(a) is the surviving or continuing
corporation and immediately after such

                                       11
<PAGE>   12

Change in Control less than fifty percent (50%) of the total combined voting
power of its voting stock is held by another corporation or by other
corporations that are members of an affiliated group within the meaning of
Section 1504(a) of the Code without regard to the provisions of Section 1504(b)
of the Code, the outstanding Options shall not terminate unless the Committee
otherwise provides in its sole discretion.

         9.       NONTRANSFERABILITY OF OPTIONS.

                  Unless otherwise specifically provided in an Option Agreement,
during the lifetime of the Optionee, an Option shall be exercisable only by the
Optionee or the Optionee's guardian or legal representative. No Option shall be
assignable or transferable by the Optionee, except by will or by the laws of
descent and distribution.

         10.      COMPLIANCE WITH SECURITIES LAW.

                  The grant of Options and the issuance of shares of Stock upon
exercise of Options shall be subject to compliance with all applicable
requirements of federal, state and foreign law with respect to such securities.
Options may not be exercised if the issuance of shares of Stock upon exercise
would constitute a violation of any applicable federal, state or foreign
securities laws or other law or regulations or the requirements of any stock
exchange or market system upon which the Stock may then be listed. In addition,
no Option may be exercised unless (a) a registration statement under the
Securities Act shall at the time of exercise of the Option be in effect with
respect to the shares issuable upon exercise of the Option or (b) in the opinion
of legal counsel to the Company, the shares issuable upon exercise of the Option
may be issued in accordance with the terms of an applicable exemption from the
registration requirements of the Securities Act. The inability of the Company to
obtain from any regulatory body having jurisdiction the authority, if any,
deemed by the Company's legal counsel to be necessary to the lawful issuance and
sale of any shares hereunder shall relieve the Company of any liability in
respect of the failure to issue or sell such shares as to which such requisite
authority shall not have been obtained. As a condition to the exercise of any
Option, the Company may require the Optionee to satisfy any qualifications that
may be necessary or appropriate, to evidence compliance with any applicable law
or regulation and to make any representation or warranty with respect thereto as
may be requested by the Company.

                                       12
<PAGE>   13

         11.      INDEMNIFICATION.

                  In addition to such other rights of indemnification as they
may have as members of the Board or officers or employees of the Participating
Company Group, members of the Board or the Committee and any officers or
employees of the Participating Company Group to whom authority to act for the
Board or the Committee or the Company is delegated shall be indemnified by the
Company against all reasonable expenses, including attorneys' fees, actually and
necessarily incurred in connection with the defense of any action, suit or
proceeding, or in connection with any appeal therein, to which they or any of
them may be a party by reason of any action taken or failure to act under or in
connection with the Plan, or any right granted hereunder, and against all
amounts paid by them in settlement thereof (provided such settlement is approved
by independent legal counsel selected by the Company) or paid by them in
satisfaction of a judgment in any such action, suit or proceeding, except in
relation to matters as to which it shall be adjudged in such action, suit or
proceeding that such person is liable for gross negligence, bad faith or
intentional misconduct in duties; provided, however, that within sixty (60) days
after the institution of such action, suit or proceeding, such person shall
offer to the Company, in writing, the opportunity at its own expense to handle
and defend the same.

         12.      TERMINATION OR AMENDMENT OF PLAN.

                  The Board may terminate or amend the Plan at any time.
However, subject to changes in applicable law, regulations or rules that would
permit otherwise, without the approval of the Company's stockholders, there
shall be (a) no increase in the maximum aggregate number of shares of Stock that
may be issued under the Plan (except by operation of the provisions of Section
4.2), (b) no change in the class of persons eligible to receive Incentive Stock
Options, and (c) no other amendment of the Plan that would require approval of
the Company's stockholders under any applicable law, regulation or rule. In any
event, no termination or amendment of the Plan may adversely affect any then
outstanding Option or any unexercised portion thereof, without the consent of
the Optionee, unless such termination or amendment is required to enable an
Option designated as an Incentive Stock Option to qualify as an Incentive Stock
Option or is necessary to comply with any applicable law, regulation or rule.

         13.      STOCKHOLDER APPROVAL.

                  The Plan or any increase in the maximum number of shares of
Stock issuable thereunder as provided in Section 4.1 (the "MAXIMUM SHARES")
shall be approved by the stockholders of the Company within twelve (12) months
of the date of adoption thereof by the Board. Options granted prior to
stockholder approval of the Plan or in excess of the Maximum Shares previously
approved by the stockholders shall become exercisable no earlier than the date
of stockholder approval of the Plan or such increase in the Maximum Shares, as
the case may be.

                                       13<PAGE>   1
                                                                   EXHIBIT 10.4

                        MEDICAL COLLEGE OF HAMPTON ROADS
                     D/B/A EASTERN VIRGINIA MEDICAL SCHOOL,

                               MCGILL UNIVERSITY

                                      AND

                           GMP ENDOTHERAPEUTICS, INC.

                               LICENSE AGREEMENT

<PAGE>   2

                               LICENSE AGREEMENT

          THIS AGREEMENT (the "Agreement"), dated as of the 31st day of
January, 2000 is by and among GMP ENDOTHERAPEUTICS, INC.("Licensee"), One East
Broward Blvd, Suite 1701 Fort Lauderdale, Fl 33301, Medical College of Hampton
Roads d/b/a Eastern Virginia Medical School, 358 Mowbray Arch, Suite 401,
Norfolk, Virginia 23507 ("EVMS") and McGill University, 3550 University Street,
Montreal, Quebec, Canada H3A 2A7 ("McGill") (EVMS and McGill jointly referred
to as Licensor).

                                    RECITALS

         1.       EVMS and McGill possess information and intellectual property
rights concerning human Pancreatic Beta Cell Growth Factor.

         2.       EVMS and McGill jointly, or EVMS individually, are the owners
of certain patents and patent applications identified in Appendix A, along with
any divisions, continuations, reissues, reexaminations, continuations-in-part
("CIPs"), and any foreign applications and patents issuing therefrom directed
to formulations of islet neogenesis associated proteins ("INGAP"), INGAP genes,
reagents for regulating INGAP expression or activity, and uses thereof
(collectively herein the "Licensed Patent Rights");

         3.       Licensee is in the business of developing and commercializing
therapeutic and diagnostic products and desires to obtain an exclusive,
worldwide, license with respect to the compounds, processes, and uses which are
the subject matter of the Patents and related technology; and

         4.       EVMS, McGill and Global Medical Products, Inc.("GMP"), an
Affiliate of Licensee, have entered into a Letter of Intent as the same has
been extended by the parties (the "Letter of Intent") and now wish to enter
into a binding license agreement that includes the concepts stated in the
Letter of Intent.

          NOW THEREFORE, in consideration of the premises and mutual covenants
contained herein, the parties agree as follows:

                                   Article I
                                  Definitions

         Section 1.0. General. Terms defined in this Article I, and
parenthetically elsewhere, shall have the same meaning throughout this
Agreement. Defined terms may be used in the singular or plural.

         Section 1.1. "Affiliate" means any entity that directly or indirectly
controls, is controlled by or is under common control with Licensee. The term
"control" as used herein means the possession of the power to direct or cause
the direction of the management and the policies of an entity, whether through
the ownership of a majority of the outstanding voting securities or by

<PAGE>   3

contract or otherwise.

         Section 1.2. "Confidential Information" means all materials, Know-How
or other information directly related to INGAP, including, without limitation,
proprietary information, designs, methods, processes, specifications and
materials (whether or not patentable) regarding a party's technology, products,
business information or objectives.

         Section 1.3. "Controlled" means the ability to grant a license or
sublicense as provided herein without violating the terms of any agreement with
a Third Party.

         Section 1.4. "Compound" means mammalian Islet Neogenesis Associated
Protein (INGAP) together with all derivatives, peptides, analogs and fusion
proteins or peptides thereof, nucleic acids encoding any of the above and small
molecule modulators (agonist or antigonist) of any of the above which is
covered by one or more Valid Claims of the Licensed Patent Rights.

         Section 1.5. "Know-How" means all information, data or materials
directly related to INGAP, including without limitation: instructions;
processes; formulae; biological and chemical materials; and biological,
chemical, pharmacological, toxicological, pharmaceutical, physical and
analytical, clinical, safety, manufacturing and quality control data and
information, all of which is unpatented.

         Section 1.6. "Licensed Know-How" means Know-How necessary to make, use
or sell a Licensed Product that is owned or Controlled by either Licensor as of
the date of this Agreement. Licensed Know-How does not include Licensed Patent
Rights.

         Section 1.7. "Licensed Patent Right" means a Patent Right that is
owned or Controlled, or becomes owned or Controlled, by either Licensor during
the term of this Agreement covering a method, apparatus, material, or
manufacture that is based upon, or claims priority from or has claims dependent
upon, or corresponds to United States Patents 5,840,531; 5,834,590; or
5,804,421or any patent application upon which these patents are based or claim
priority to, including all corresponding foreign and international patent
applications and patents issuing therefrom. Licensed Patent Rights existing as
of the date of this Agreement are listed in Appendix A which is attached hereto
and made a part of this Agreement. Licensed Patent Rights do not include
Licensed Know-How.

          Section 1.8. "Licensed Product" means a composition intended for use
as a therapeutic, pharmaceutical or diagnostic comprising a Compound or any
product otherwise covered by a valid claim of Licensed Patent Rights.

         Section 1.9. "Licensed Technology" means the Licensed Patent Rights
and Licensed Know-How.

         Section 1.10 "Licensee" means GMP ENDOTHERAPEUTICS, INC.

         Section 1.11. "Licensor" means EVMS and/or McGill.

         Section 1.12. "Net Sales" means the gross amount received by Licensee
or its Affiliates from their sales to Third Parties of Licensed Product less:

         (a)      Trade, quantity and cash discounts allowed;

         (b)      Discounts, refunds, rebates, chargebacks, and retroactive
                  price adjustments;

         (c)      Licensed Product returns and allowances;

         (d)      Any tax imposed on the product that is appropriately deducted
                  from sales under generally accepted accounting principles;

         (e)      Any other reasonable and customary deductions which according
                  to generally

<PAGE>   4

                  accepted accounting principles ("GAAP") are bona fide
                  deductions from gross sales to determine net sales, which
                  deductions shall be subject to audit in accordance with
                  Section 4.9 of this Agreement; and

         (f)      Any shipping, freight, storage, insurance and other
                  transportation and handling charges

         Such amounts shall be determined from the books and records of
Licensee maintained in accordance with GAAP, consistently applied.

         Section 1.13 "Patent Right" means an unexpired patent or pending
patent application and all patents issuing therefrom and all divisions,
continuations, continuations-in-part, reissues, re-examination applications,
extensions, supplementary protection certificates, certificates of additions,
inventor's certificates, and any similar intellectual property, including all
foreign and international counterparts thereof.

         Section 1.14. "Phase I Clinical Trials" means small scale human
clinical trials approved by the FDA conducted in volunteers in the United
States and designed to indicate product safety. Successful completion of such
Phase I Clinical Trials shall be deemed to have occurred if, based on the
results of such Phase I Clinical Trials, Licensee decides to conduct Phase II
Clinical Trials on such Licensed Products.

         Section 1.15. "Phase II Clinical Trials" means small scale human
clinical trials conducted by or through Licensee in patients and designed to
indicate a statistically significant level of efficacy in the particular
indication tested, as well as to obtain some indication of the dosage regimen
required.

         Section 1.16. "Phase III Clinical Trials" means large scale human
clinical trials approved by the FDA conducted by Licensee in patients in the
United States and designed to establish efficacy of a Licensed Product in the
particular indication tested and required to obtain clinical registration of a
Licensed Product with health regulatory authorities.

          Section 1.17. "Registration Approval" means in relation to a Licensed
Product, such approval by the appropriate governmental authorities of the
United States, such approval being legally required before such Licensed
Product may be commercialized or sold for use in humans.

         Section 1.18. "Sublicense Fees" means the net amounts received by
Licensee from non Affiliates based upon the sale, use or manufacture of
Licensed Products less any discounts, rebates, credits, allowances, taxes or
other bona fide deductions from gross receipts to determine net revenues, which
deductions shall be subject to audit in accordance with Section 4.9 of this
Agreement.

         Section 1.19. "Third Party" means any person or entity other than
Licensee, EVMS or McGill, or an Affiliate or Sublicensee of Licensee, EVMS or
McGill.

         Section 1.20. "Valid Claim" means any claim(s) in a pending patent
application or in an unexpired issued patent which has not been denied or held
unenforceable, unpatentable or invalid by a decision of a court or other
governmental agency of competent jurisdiction, unappealable or unappealed
within the time allowed for appeal, and which has not been admitted to be
invalid or unenforceable through reissue, reexamination ,disclaimer or similar
procedure. If in any country there should be two or more such decisions
conflicting with respect to the validity of the same claim, the decision of the
higher or highest tribunal shall thereafter control; however, should the
tribunals be of equal rank, then the decision or decisions upholding the claim
shall prevail when the decisions are equal in number, and the majority of
decisions shall prevail when the

<PAGE>   5

conflicting decisions are unequal in number.

                                   Article II
                           Initiation and Development

         Section 2.0. Prior Information. All EVMS and McGill Know-How or
Confidential Information received by Licensee prior to the date of this
Agreement shall be considered to be Licensed Know-How and treated in accordance
with the terms and conditions of this Agreement.

         Section 2.1. Administration. For purposes of administering,
interpreting or otherwise carrying out the terms and conditions of this
Agreement, EVMS and McGill have mutually designated EVMS as the administrator
of this Agreement (the "Administrator"). The Administrator shall be Licensee's
contact for compliance with any terms or conditions hereof. However, all
correspondence, notices and reports to the Licensor shall be directed to both
EVMS and McGill. as set forth in Section 10.7 below. Any action to be taken or
notices under this Agreement which specifically stipulate that such action is
to be taken jointly by the Licensors rather than the Administrator must be
evidenced by the signatures of each of the representatives designated under
Section 10.7 by EVMS and McGill.

         Section 2.2. Responsibilities. Licensee shall have responsibility for
the registration submission, registration approval, manufacturing, and
marketing of all Compounds and Licensed Products, and for payment of all costs,
associated therewith. Licensee shall be entitled to consult with Drs. Aaron
Vinik and Georges of Eastern Virginia Medical School as such entities and
persons may agree, regarding Licensee's efforts to develop, approve and market
Licensed Products.

         Section 2.3. Reports. Licensee shall submit written reports to the
Licensor at the request of the Licensor summarizing the status of Licensee's
efforts in regard to Licensed Products and Licensee's planned efforts for the
following six months. The Licensor may request such written reports no more
than two (2) times per calendar year. Such reports shall be subject to the
confidentiality and non-use obligations set forth in Article VI.

         Section 2.4. Compliance. Licensee shall comply with all United States
federal rules, regulations and guidelines applicable to the use of Licensed
Technology and assume full responsibility for any claims or liabilities which
may arise as a result of Licensee's use or possession of Licensed Technology.

         Section 2.5. Diligence. Licensee agrees to exercise reasonably
diligent efforts toward commercializing Licensed Products according to its
usual business practices for products of similar potential and value.

                                  Article III
                                 License Grant

         Section 3.0. License Grant. Subject to the terms and conditions of
this Agreement, Licensor hereby grants to Licensee : (i) a worldwide, exclusive
license to use the Licensed Patent Rights and to make, have made, use, have
used, develop, have developed, import, market, offer for sale, sell, and have
sold Compound and Licensed Products; and (ii) a worldwide, non-

<PAGE>   6
*** CONFIDENTIAL INFORMATION OMITTED AND FILED SEPARATELY WITH THE SECURITIES
    AND EXCHANGE COMMISSION. ASTERISKS DENOTE SUCH OMISSIONS.

exclusive license to use the Licensed Know How in connection with the
exploitation of the Licensed Patent Rights granted to Licensee hereunder.

The license granted to Licensee hereunder in the Licensed Patent Rights shall
be exclusive in all respects, except that Licensor specifically reserves the
right to use the Licensed Patent Rights for their continuing research only,
such research to include research sponsored by any non-commercial Third Party.
For the sake of clarity, Licensor confirms that its reserved right under this
paragraph shall not include the right to grant other licenses of the Licensed
Patent Rights.

During the term of this Agreement and from time to time the Licensor shall,
from time to time, upon written request of Licensee, disclose, or in the case
of materials, provide to Licensee, any Licensed Know How, provided that
Licensee shall pay all reasonable costs incurred by Licensor in providing such
information.

         Section 3.1. Sublicense. Licensee shall have the right to grant
sublicenses to any entity not an affiliate with respect to the rights conferred
upon Licensee under this Agreement to make, have made, use, have used, import,
market, offer for sale, sell, and have sold Compound and Licensed Products.
Licensee shall provide a copy of any such sublicenses to the Licensor.

                                   Article IV
                                Commercial Terms

         Section 4.0. License Fees. Subject to the terms and conditions of this
Agreement, Licensee shall pay Licensor the following license fees:

         (a)      [***] upon the date of this Agreement;

         (b)      [***] upon the first anniversary of the date of this
                  Agreement; and

         (c)      reimbursement for all patent fees incurred prior to the date
                  of this Agreement in connection with the grant of the Patents
                  for which reimbursement has not previously been made; which
                  amounts shall not exceed $ 39,000.

         Section 4.1. Milestones. Subject to the terms and conditions of this
Agreement, including Section 4.3(b) hereof, Licensee shall make the following
non-refundable and non-creditable milestone payments to the Licensor:

         (a)      [***] upon receipt of the first approval of the use of a
                  product covered by a Valid Claim (herein "Patented Product")
                  in animals by the USDA or other regulatory agencies of the
                  United States;

         (b)      [***] upon initiation of the first Phase I Clinical
                  Trials;

         (c)      [***] upon successful completion of Phase III Clinical
                  Trials of a Licensed Product;

         (d)      [***] upon Registration Approval;

<PAGE>   7
*** CONFIDENTIAL INFORMATION OMITTED AND FILED SEPARATELY WITH THE SECURITIES
    AND EXCHANGE COMMISSION. ASTERISKS DENOTE SUCH OMISSIONS.

         Section 4.2. Stock.

         Licensee has this date issued to Licensor shares of its common stock
                  in such amounts that after issuance of those shares Licensor
                  shall own in the aggregate, [***] of the total outstanding
                  shares of the common stock of Licensee, on a fully diluted
                  basis. Such shares are being issued this even date in
                  accordance with the terms and conditions of the Stock
                  Purchase Agreements between Licensee and each Licensor.

         Section 4.3. Payments.

         (a)      Any payment accruing under Sections 4.0 and 4.1 shall be made
                  to the Administrator within thirty (30) days of such accrual.
                  The Administrator shall distribute to McGill within two (2)
                  business days any share of payments due to McGill.

         (b)      The milestone payments under Section 4.1 shall be payable by
                  Licensee only one time, regardless of the number of Licensed
                  Products developed or sold by Licensee or any Sublicensee.

         (c)      In the event that Licensee does not make the payments to the
                  Licensor in accordance with Sections 4.1 (a), (b) and (c)
                  within five (5) years from the date of this Agreement, the
                  Licensor shall thereafter have the right to terminate this
                  Agreement in accordance with Section 7.1 below (including the
                  notice and right to cure by Licensee), unless Licensee makes
                  a payment to the Licensor of [***] United States dollars, less
                  any amounts paid by Licensee under such Sections, within 60
                  days after receiving written notice of such election. If such
                  payment is made, the remaining payments under Sections 4.1
                  (a), (b) and (c) shall be waived.

         Section 4.4. Royalties. Subject to the terms and conditions of this
Agreement, Licensee shall:

         Pay royalties to Licensor on Licensed Products equal to [***] of Net
         Sales during the term of this Agreement. EVMS and McGill shall each
         independently have the option to exchange with GMP their proportionate
         interest in such royalty stream for shares of Licensee common stock
         representing, in the aggregate,  [***] shares of Common Stock of the
         Licensee (the "Total Option Shares") (which is in addition to the [***]
         of the Common Stock of the Licensee issued to the Licensor this even
         date provided that the Licensors exercise this option to exchange by
         the earlier of [***] years from the date of this Agreement or 30 days
         after receiving written notice from Licensee to the Administrator that
         the Licensee has entered into a Letter of Intent with an underwriter
         for an initial public offering of Licensee securities or such other
         periods as the parties may agree, in writing. In the event that one of
         the Licensors, but not both, elect shares in lieu of royalties
         pursuant to this Section (the "Electing Licensor"), that Licensor
         shall receive its pro-rata share of the Total Option Shares based upon
         the ratio that the royalty rate percentage of Net Sales to which that
         Licensor is entitled bears to the total [***] Royalty Rate (the
         "Electing Licensor Percentage"). If after such exchange there remains
         a Licensor that has not exercised this exchange right, the royalty
         rate due from Licensee on

<PAGE>   8
*** CONFIDENTIAL INFORMATION OMITTED AND FILED SEPARATELY WITH THE SECURITIES
    AND EXCHANGE COMMISSION. ASTERISKS DENOTE SUCH OMISSIONS.

         Net Sales and Sublicense Fees shall be reduced by the Electing
         Licensor Percentage; which remaining sums shall be paid to the non
         Electing Licensor through the Administrator. For example, if one
         Licensor was entitled to 40% of the royalty fees (i.e [***] of Net
         Sales and  [***] of Sublicense Fees) and elected to exchange that
         interest for shares of Common Stock, that Electing Licensor would
         receive 40% of the [***] shares and the royalty rate on the Net Sales
         and Sublicensing Fees would be reduced by 40% which would result in an
         on- going royalty on Net Sales of [***] and on Sublicense Fees, [***].
         Any such election shall be made by the respective Licensor acting
         through the Administrator who shall notify Licensee of such election
         and provide Licensee with the name of the Electing Licensor and the
         Electing Licensor Percentage. Any shares of Common Stock issued under
         this Section shall have the same restrictions and limitations imposed
         on the securities of Licensee issued to each Licensor this even date
         and the Electing Licensor agrees to execute such documents as are
         necessary to evidence such fact.

         (b)      Pay Licensor [***] of all Sublicense Fees for so long as
         Licensee is obligated to pay Licensor any ongoing royalty fees as
         described above in Section 4.4 (a), but subject to adjustment as
         provided in that Section if only one Licensor exercises the exchange
         for stock option.

         Section 4.5. Term of Royalty Payment. Royalties paid by Licensee
pursuant to Section 4.4 shall be payable on a country-by-country basis from the
date of the first commercial sale of each Licensed Product in a particular
country until expiration of the last to expire Licensed Patent Right in such
country with respect to which a Valid Claim covers such Licensed Product.

         Section 4.6. Single Royalty. Royalties under Section 4.4 will be
payable only once on a Licensed Product regardless of the existence of more
than one Licensed Patent Right applicable to such Licensed Product.

         Section 4.7. Stacking Provisions. Royalties payable under Section 4.4
shall be reduced by the amount of any royalty payments due by Licensee on the
Licensed Products with respect to other patent rights; provided, however, that
such payments shall not reduce the amount of the royalties due Licensor by more
than 50% of the royalty otherwise due to Licensor under Section 4.4, and
further provided such payments shall not reduce the percentage ownership of
stock that either McGill or EVMS owns or may elect to own under Section 4.4.

         Section 4.8. Payments. Royalty payments hereunder shall be made to the
Administrator quarterly within sixty (60) days following the end of each
calendar quarter for which royalties are due and shall be made in United States
dollars. Each royalty payment shall be accompanied by a statement stating the
Net Sales of Licensed Product and Sublicense Fees during the relevant three (3)
month period. Licensee's then current standard exchange rate methodology will
be employed for the translation of foreign currency sales into United States
dollars. This methodology is used by Licensee in the translation of its foreign
currency operating results for external reporting, is consistent with generally
accepted accounting principles, and is audited by Licensee's independent
certified public accountants in connection with the audit of the consolidated
financial statement of Licensee.

          Section 4.9. Records. Licensee shall keep and maintain records of
sales of Licensed Product. Such records shall be open to inspection not more
than once per year upon at least ten (10) days written notice to Licensee at
any reasonable time within one (1) year after the royalty

<PAGE>   9
*** CONFIDENTIAL INFORMATION OMITTED AND FILED SEPARATELY WITH THE SECURITIES
    AND EXCHANGE COMMISSION. ASTERISKS DENOTE SUCH OMISSIONS.

period to which such records relate, by an independent certified public
accountant that is acceptable to both parties and such inspection shall be at
Licensor's expense. The independent certified public accountant shall have the
right to examine the records kept pursuant to this Section 4.9 and report to
the Licensor the findings of said examination of records insofar as necessary
to verify the statements made pursuant to Section 4.8. Said findings shall be
considered Confidential Information of Licensee.

         Section 4.10. Taxes. Any and all taxes levied on royalties accruing
under this Article shall be paid by Licensor. If laws or regulations require
withholding of said taxes, such taxes will be deducted by Licensee from such
remittable royalty and will be paid by Licensee to the proper taxing authority,
and proof of payment shall be sent to Licensor annually within ninety (90) days
following December 31st of each reporting year.

         Section 4.11. Foreign Sales. The remittance of royalties payable on
sales outside the United States shall be payable to Licensor in United States
Dollar equivalents in accordance with the rate of exchange provided in Section
4.8 hereof for the last business day of the calendar quarter in which the
royalties are payable. If the transfer of or the conversion into the United
States Dollar equivalents of any such remittance in any such instance is not
lawful or possible, the payment of such part of the royalties as is necessary
shall be made by the deposit thereof, in the currency of the county where the
sale was made on which the royalty was based to the credit and account of
Licensor or its nominee in any commercial bank or trust company of Licensor's
choice located in that country, prompt written notice of which shall be given
by Licensee to Licensor.

         Section 4.12. Other Financial Commitments. The Licensee and EVMS have
this date entered into a Research Funding Agreement pursuant to which Licensee
agrees to provide sponsored research and development activities with EVMS
related to the Licensed Products in the annual amount of [***], for [***]
years, for a total of  [***] USD. The failure of Licensee to fund such
research shall constitute a material breach of this Agreement, subject to the
provision of Section 7.1 below.

                                   Article V
                         Intellectual Property Matters

         Section 5.0. Patent Prosecution. The Licensee, at its own expense,
shall be responsible for filing, prosecuting and maintaining all patents and
patent applications specified under Licensed Patent Rights, and the Licensee
shall be licensed there under as provided herein. Title to all such patents and
patent applications shall reside in EVMS or McGill, jointly or solely based on
ownership.. Licensor owned patents and patent applications which are filed,
prosecuted or maintained by other than Licensor retained counsel shall be
filed, prosecuted and maintained in the best interest of Licensor. Such counsel
shall acknowledge that they represent Licensor. The Administrator shall be
copied directly on all patent correspondence, provided copies of all
correspondence received from any patent office and provided drafts of any
papers or applications to be filed at least two weeks prior to patent office
submission for Licensor comment. Based on ownership of the application or
patent, EVMS and/or McGill comments shall be considered and reasonably
incorporated. The Licensor having ownership of the application or patent shall,
at its own expense, reasonably cooperate with patent counsel by providing
reasonable consultations in

<PAGE>   10

connection with such matters. Such patent counsel shall not file any
applications which incorporate new matter or new applications in which
inventorship has been changed from that of the originally filed patents within
Licensed Patent Right without written permission of the Administrator. Should
applications not be prosecuted in Licensor's best interest, as reasonably
determined by the Administrator, the Administrator may revoke the power of
attorney granted to the non-Licensor retained counsel. In any country where
the Licensee elects not to have a patent application filed or to pay expenses
associated with filing, prosecuting, or maintaining a patent application or
patent, EVMS and or McGill, based on ownership of the invention, may file,
prosecute, and/or maintain a patent application or patent at its own expense
and for its own exclusive benefit and the Licensee thereafter shall not be
licensed under such patent or patent application in that country.

         Section 5.1. Third Party Infringement. In the event Licensee shall
have received actual notice of a substantial infringement of a Licensed Patent
Right, Licensee shall have the first right, within six months of receiving
notice, to either (i) initiate the appropriate steps to stop the infringement,
(ii) file suit against the infringer, or (iii) provide Licensor with reasonable
evidence showing that the infringer intends to enter into a settlement
agreement in which future infringement will be halted. Any recoveries from such
infringement actions will first be applied to reimbursement of the reasonable
expenses incurred by the Licensee in the prosecution of the case and the
remainder shall be treated as Sublicense Fees. Should Licensee decide not to
enforce the Licensed Patent Rights against such infringement, Licensor shall
have the right, at its own expense and for its own benefit, to bring any action
it deems necessary to stop the infringement and recover for its own benefit
damages, profits, and awards which might be obtained. In any infringement
action instituted by either party under this Section, the other party agrees to
cooperate, to the extent reasonably required in such action and shall be
entitled to reimbursement of reasonable third party costs incurred by it and
and other direct costs incurred in connection with such activities which
require substantial efforts. No settlement or consent judgment or other
voluntary final disposition of a suit under this Section 5.1 may be entered
into without the joint consent of Licensor and Licensee (which consent shall
not be withheld unreasonably).

         Section 5.2. Patent Term Extensions. The parties shall cooperate with
each other in gaining patent term extensions wherever applicable to Licensed
Patent Rights covering a Licensed Product. Licensee shall determine which
patents shall be extended. All filings for such extension shall be made by
Licensor after consultation with Licensee, provided, however, that in the event
that Licensor elects not to file for an extension, Licensor shall (i) inform
Licensee of its intention not to file and (ii) grant Licensee the right to file
for such extension.

                                   Article VI
                                Confidentiality

         Section 6.0. Licensee Obligations. Licensee agrees to maintain in
strict confidence all Confidential Information pertaining to this Agreement
received from Licensor to the same extent and in the same manner Licensee
maintains its own confidential information and not to use Confidential
Information received from Licensor during the term of the Agreement, except as

<PAGE>   11

otherwise provided for in this Agreement. The obligations of confidentiality
and non-use shall expire five (5) years from the date of disclosure of the
Confidential Information.

         Section 6.1. Licensor Obligations. Licensor agrees to maintain in
strict confidence all Confidential Information pertaining to this Agreement
received from Licensee to the same extent and in the same manner Licensor
maintains its own confidential information and not to use Confidential
Information received from Licensee during the term of the Agreement, except as
otherwise provided for in this Agreement. The obligations of confidentiality
and non-use shall expire five (5) years from the date of disclosure of the
Confidential Information.

         Section 6.2. Exceptions. Non-disclosure and non-use obligations of
Licensee and the Licensor shall not apply to Confidential Information that:

         a)       was known to the receiving party or to the public prior to
                  the disclosure by the disclosing party; or

         b)       becomes known to the public from a source other than the
                  receiving party; or

         c)       is disclosed to the receiving party by a third party having a
                  legal right to make the disclosure;

         d)       is required by law to be disclosed; or

         e)       is independently developed by the recipient.

         Section 6.3. Publications. Licensor agrees to provide Licensee with
written notice of any press releases or other publication or dissemination of
information by Licensor or either of them that makes reference to this
Agreement, the relationship to Licensee or the Licensed Patent Rights, which
notice shall be given to Licensee as soon as reasonably possible, it being the
desire of the Licensee to be able to knowledgeably respond to inquires
resulting from the Licensor's disclosures.

<PAGE>   12

                                  Article VII
                              Term and Termination

         Section 7.0. Agreement Term. This Agreement shall become effective on
the date of this Agreement and shall terminate on the later of (a) the last to
expire of the Licensed Patent Rights, or (b) the expiration of all royalty
obligations pursuant to Article IV unless terminated earlier pursuant to this
Agreement.

         Section 7.1. Early Termination. If any party is in default of any of
its material obligations under this Agreement and fails to remedy that default
within ninety (90) days after the other party sends written notice of the
default, the party not in default may terminate this Agreement immediately by
giving written notice of the termination. The termination date shall be the
date of the notice of termination. If either or both Licensor has defaulted,
the licenses granted hereunder shall survive. If Licensee has defaulted, the
licenses granted hereunder shall terminate upon termination for default.

         Licensee may terminate this Agreement on the fifth anniversary date of
the date of this Agreement by giving written notice of such election to the
Licensor at least sixty (60) days before such date.

         Section 7.2. Effect of Termination. Termination of this Agreement
shall not affect the rights and obligations of the parties accrued under this
Agreement prior to termination. In particular, the following survive expiration
or termination of this Agreement:

         (a)      Obligations to pay all License Fees in Section 4.0, and
                  royalties, milestone payments and other sums accruing
                  hereunder up to the date of termination;

         (b)      The right to complete the manufacture and sale of Licensed
                  Products, which qualify as "work in process" under generally
                  accepted cost accounting standards or which are in stock at
                  the date of termination, and the obligation to pay royalties
                  on Net Sales or Sublicense Fees of such Products;

         (c)      The obligations of confidentiality set forth in Article VI
                  for the period stated therein;

         (d)      The obligations for record keeping and accounting reports for
                  so long as Licensed Products are sold. At such time after
                  termination of this Agreement when sales or other
                  dispositions of Licensed Products have ceased, Licensee shall
                  render a final report along with any royalty payment due;

         (e)      Licensors' right to inspect books and records as described in
                  Article IV;

         (f)      Licensor's ownership of stock in Licensee.

7.3      Section 7.3. Sublicensees. In the event this Agreement is terminated
         as a result of a breach by Licensee hereunder, any Sublicense
         Agreement shall continue in force if such Sublicensee agrees to make
         all future payments to the Administrator and cures all monetary
         defaults of the Licensee hereunder.

<PAGE>   13

7.4      Section 7.4. Estoppel Certificates. The Administrator, acting on
         behalf of the Licensor, shall, from time to time, upon written request
         of Licensee, any of its Affiliates or sublicensees or potential
         sublicensees, issue an estoppel certificate to the requesting entity
         setting forth the status of this Agreement, and, if in default,
         stipulating the actions necessary to cure such default.

7.5      Section 7.5. Data. Upon termination of this Agreement, Licensee shall
         provide the Administrator all data developed by Licensee related to
         the Compound or Licensed Product, including all data necessary or
         helpful to obtain or maintain required government approvals to
         commercialize the Compound or Licensed Product.

                                  ARTICLE VIII
                          COMPLIANCE WITH EXPORT LAWS

         Section 8.0. Authority. This Agreement is subject to any restrictions
concerning the export of products or technical information from the United
States, which may be imposed upon Licensor or Licensee from time to time by the
government of the United States. Furthermore, all parties hereto agree that
they will not export, directly or indirectly, any technical information
acquired from another under this Agreement or any products using such technical
information to any country for which the United States government or any agency
thereof at the time of export requires an export license or other governmental
approval, without first obtaining the written consent to do so from the
Department of Commerce or other agency of the United States government when
required by an applicable statute or regulation. Licensor make no
representation that an export license or other approval for the export of
Licensed Products is available.

<PAGE>   14

                                   Article IX
                                Indemnification

         Licensee shall indemnify, defend and hold Licensor harmless from and
against any losses, claims, liabilities, costs, and expenses (including
reasonable attorneys' fees) that may be imposed upon or asserted against
Licensor as a result of the manufacture, use, or sale of any Licensed Product,
or the use of any Licensed Technology, by Licensee, its authorized agents or
sublicensees, except for those arising from intentional torts or negligence on
the part of Licensor. Either Licensor seeking such indemnification agrees to
give Licensee written notice of any such matters promptly after learning of
such claims or the possible assertions of the same and will cooperate in the
defense of such matters; which defense will be provided and paid for by
Licensee. At such time as the Licensee begins to sell or distribute Licensed
Products for commercial use it shall procure and maintain Products Liability
insurance in coverage amounts of not less than $5,000,000 and naming the
Licensors as additional insureds.

                                   Article X
                            Miscellaneous Provisions

         Section 10.0. Disclosure Rights. Subject to applicable laws and
regulations, and anything to the contrary contained in this Agreement
notwithstanding, Licensee shall have the right to publish and otherwise
disseminate information concerning this Agreement and the Licensed Technology
that Licensee determines is appropriate in order to comply with applicable
governmental orders or governing laws and regulations without prior approval by
Licensor. Licensor agrees to review and, if requested, consider an approval, in
writing of any materials presented by Licensee for dissemination, which
approval shall not be unreasonably withheld and shall be responded to within 5
business days of the written request.

         Section 10.1. Representations and Warranties. Each Licensor represents
and warrants to Licensee that; (i ) as of the date of this Agreement such
Licensor does not have any inventions or discoveries, including pending patent
application or issued patents, relating to INGAP proteins or their use in
therapeutic, diagnostic or pharmaceutical applications that are not listed on
Appendix A; (ii) it and the other Licensor are the sole and/or joint and
exclusive owners of the respective Licensed Patent Rights listed on Appendix A
and that the interests therein conveyed under this Agreement are free and clear
of any liens, claims, options, licenses or other encumbrances of any nature
except those granted to Licensee hereunder; (iii)it has the requisite power and
authority to convey the interests in the Licensed Technology as provided in
this Agreement; (iv) the entering into and performance under this Agreement by
such Licensor will not create a default under or breach of any agreements with
third parties; (v) in reliance upon the opinion of Foley and Lardner, Eli Lilly
has no rights, options or other interest in, or claim to, any of the Licensed
Patent Rights: and (vi) without having conducted any investigation into the
matter, such Licensor is not aware of any facts that could give rise to any
claim that any of the Licensed Patent Rights infringes upon any third party's
intellectual property or aware of any infringement by any

<PAGE>   15

third party upon any of the License Patent Rights. EXCEPT AS PROVIDED ABOVE,
LICENSOR MAKE NO WARRANTIES CONCERNING ANY LICENSED TECHNOLOGY, OR LICENSED
PATENT RIGHTS THAT MAY BE SUBJECT TO THIS AGREEMENT. WITHOUT LIMITING THE
FOREGOING, LICENSOR DO NOT REPRESENT OR WARRANT SUCCESSFUL COMMERCIALIZATION OF
LICENSED PRODUCTS OR THE SAFETY OR EFFICACY OF LICENSED PRODUCTS. LICENSOR MAKE
NO EXPRESS OR IMPLIED WARRANTY, INCLUDING BUT NOT LIMITED TO ANY WARRANTY OF
MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, AS TO ANY LICENSED
PRODUCT, LICENSED PATENT OR LICENSED TECHNOLOGY. LICENSOR MAKE NO WARRANTY OR
REPRESENTATION AS TO THE VALIDITY OR SCOPE OF ANY LICENSED PATENT RIGHTS OR
THAT ANY LICENSED PRODUCT WILL BE FREE FROM ANY INFRINGEMENT OF PATENTS OF
THIRD PARTIES, OR THAT NO THIRD PARTIES ARE IN ANY WAY INFRINGING LICENSED
PATENT RIGHTS.

         Section 10.2. Use of Name. In any publications or publicity concerning
the Licensed Technology, Licensee will collaborate and consult with each
Licensor to ensure that each Licensor is provided appropriate recognition for
its contributions to the Licensed Technology. However, except as otherwise
permitted under this Agreement, the use of the name of either Licensor or any
variation thereof in connection with the advertising or sale of Licensed
Products is expressly prohibited without advance consent in writing from each
Licensor. Procedurally, the above policies shall be implemented by the
Licensee sending, in writing, to each Licensor of the proposed language. Each
Licensor agrees to promptly review and respond to the proposal from Licensee.
If no written response is received from a Licensor within 10 days following the
sending of such notice by Licensee, such Licensor shall be deemed to have
consented, in writing, to the proposed language.

         Section 10.3. No Agency. It is understood and agreed that nothing in
this Agreement shall be construed as authorization for Licensee, McGill, or
EVMS to act as agent for any other party to this Agreement. Licensee shall not
incur any liability for any act or failure to act by employees of EVMS or
McGill. EVMS or McGill shall not incur any liability for any act or failure to
act by employees of Licensee.

         Section 10.4. Dispute Resolution. Any dispute, controversy or claim
arising out of or relating to this Agreement shall be settled by arbitration
under the rules of the American Arbitration Association. All awards of the
arbitrators shall be final and binding on the parties and enforceable in any
court of competent jurisdiction. Nothing herein shall prevent a party from
seeking injunctive relief, where appropriate, from a court of competent
jurisdiction pending the outcome of any arbitration concerning the subject of
such arbitration or when authorized by an arbitrator's award or when emergency
relief is required.

         Section 10.5 Force Majeure. All parties to the Agreement shall be
excused from the performance of their obligations under this Agreement if such
performance is prevented by Force Majeure and the non-performing party promptly
provides notice of the prevention to the other parties. Such excuse shall be
continued so long as the condition constituting Force Majeure continues and the
non-performing party takes reasonable efforts to remove the condition.

<PAGE>   16

         For purposes of this Agreement, Force Majeure shall include conditions
beyond the control of the parties, including without limitation, an act of God,
voluntary or involuntary compliance with any regulation, law, or order of any
government, war, civil commotion, epidemic, failure or default of public
utilities or common carriers, destruction of production facilities or materials
by fire, earthquake, storm, or like catastrophe.

         Section 10.6. Amendment. This Agreement may not be amended,
supplemented, or otherwise modified except by an instrument in writing signed
by all parties.

         Section 10.7. Notices. Any notice required or permitted to be given
under this Agreement shall be in writing and shall be deemed to have been
sufficiently given for all purposes if mailed by first class certified or
registered mail, postage prepaid. Unless otherwise specified in writing, the
mailing addresses of the parties shall be as described below:

For Licensor:               Office of the Vice President
                            Eastern Virginia Medical School
                            358 Mowbray Arch, Suite 401
                            Norfolk, Virginia 23507
                            Attention:  Mr. David Thiel
                            Office of Technology Transfer
                            McGill University
                            3550 University Street
                            Montreal, Quebec, Canada, H3A 2A7
                            Attention:  Dr. A. Navarre, Director For McGill:

For Licensee                GMP ENDOTHERAPEUTICS, INC.
                            One East Broward Blvd.
                            Suite 1701
                            Fort Lauderdale, Florida 33301
                            Attention:  Dr. Bart Chernow

                            Copy to: Ms. Beth Arnold
                            Foley, Hoag & Eliot LLP
                            One Post Office Square
                            Boston, Massachusetts  02109
<PAGE>   17

         Section 10.8. Governing Law. This Agreement shall be governed by, and
construed in accordance with, the laws of the State of Virginia, excluding any
choice of law rules which may direct the application of the law of any other
jurisdiction. Questions affecting the construction and affect of any Patent
Rights shall be determined by the laws of the country in which the Patent Right
has been applied for and granted.

         Section 10.9. Assignment. The parties may not assign their rights and
obligations under this Agreement without the prior written consent of the
others, except Licensee may make such an assignment without the consent of
Licensor in connection with any merger, reorganization, or sale of all or
substantially all of its assets to which this Agreement relates. This Agreement
shall be binding upon and shall inure to the benefit of the successors and
permitted assigns of the parties.

         Section 10.10. Consents Not Unreasonably Withheld. Whenever provision
is made in this Agreement for any party to secure the consent or approval of
another, that consent or approval shall not unreasonably be withheld, and
whenever in this Agreement provisions are made for one party to object to or
disapprove a matter, such objection or disapproval shall not unreasonably be
exercised.

         Section 10.11. No Strict Construction. This Agreement has been
prepared jointly and shall not be strictly construed against any party.

         Section 10.12. Headings. The captions or headings of the Sections or
other subdivisions hereof are inserted only as a matter of convenience or for
reference and shall have no effect on the meaning of the provisions hereof.

         Section 10.13. Severance of Clauses. All parties agree that, should
any provision of this Agreement be determined by a court of competent
jurisdiction to violate or contravene any applicable law or policy, such
provision will be severed or modified by the court to the extent necessary to
comply with the applicable law or policy, and such modified provision and the
remainder of the provisions hereof will continue in full force and effect.

         Section 10.14. No Waiver. The waiver of a breach hereunder may be
effected only by a writing signed by the waiving party and shall not constitute
a waiver of any other breach.

         Section 10.15. Entire Agreement. This Agreement and the attachments
hereto and other agreements executed by the parties or affiliates entities this
even date constitute the entire agreement of the parties relating to the
subject matter and supercede any prior agreements relating to the subject
matter hereof.

         Section 10.16. Counterparts. This Agreement has been executed in three
(3) counterparts, all of which shall constitute an original, but which together
shall constitute the same instrument.

         Section 10.17. Surviving Rights. Termination, expiration, or
cancellation of this Agreement by any party shall not relieve the parties of
any rights or obligations accrued hereunder prior to such termination,
expiration, or cancellation.

<PAGE>   18

         IN WITNESS WHEREOF, the parties by their respective authorized
officers, have executed this Agreement.

MEDICAL COLLEGE OF HAMPTON ROADS
d/b/a EASTERN VIRGINIA MEDICAL SCHOOLGMP ENDOTHERAPEUTICS, INC.

By:                                      By:
   -------------------------------              -------------------------------
   David L. Thiel, Vice President                Bart Chernow, M.D., President
   for Administration and Finance

McGILL UNIVERSITY

By:
   -------------------------------
      Dr. Pierre E'langer
      Vice Principal for Research
      Dean of Graduate Studies

Appendix A - Schedule of Patents

<PAGE>   19

                                   APPENDIX A

TITLE:   INGAP PROTEIN INVOLVED IN PANCREATIC ISLET NEOGENESIS

Inventors:        Aaron I. Vinik, Gary L. Pittenger, Ronit Rafaeloff, Lawrence
Rosenberg and William P. Duguid

<TABLE>
<S>              <C>                          <C>                    <C>
---------------- ---------------------------- ---------------------- --------------------------------------------
Country          Patent/                      Filing Date            Assignee(s)
                 Application No.
---------------- ---------------------------- ---------------------- --------------------------------------------
U.S.             5,834,590                    2/22/95                EVMS & McGill University
---------------- ---------------------------- ---------------------- --------------------------------------------
U.S.             5,840,531                    9/9/96                 EVMS & McGill University
---------------- ---------------------------- ---------------------- --------------------------------------------
PCT              PCT/US96/01528               2/12/96                EVMS & McGill University
---------------- ---------------------------- ---------------------- --------------------------------------------
Australia        49149/96                     2/12/96                EVMS & McGill University
---------------- ---------------------------- ---------------------- --------------------------------------------
Canada           2,213,610                    2/12/96                EVMS & McGill University
---------------- ---------------------------- ---------------------- --------------------------------------------
EPO              969053685                    2/12/96                EVMS & McGill University
---------------- ---------------------------- ---------------------- --------------------------------------------
Japan            525702/96                    2/12/96                EVMS & McGill University
---------------- ---------------------------- ---------------------- --------------------------------------------
Mexico           976418                       2/12/96                EVMS & McGill University
---------------- ---------------------------- ---------------------- --------------------------------------------
</TABLE>

TITLE:   HIGH LEVEL OF EXPRESSION OF INGAP

Inventors:        Aaron I. Vinik, Gary L. Pittenger, Ronit Rafaeloff and
Scott W. Barlow

<TABLE>
<S>               <C>                         <C>                     <C>
----------------- --------------------------- ---------------------- --------------------------------------------
Country           Patent/                     Filing Date            Assignee(s)
                  Application No.
----------------- --------------------------- ---------------------- --------------------------------------------
U.S.              5,804,421                   8/12/97                EVMS
----------------- --------------------------- ---------------------- --------------------------------------------
PCT               PCT/US97/19415              10/30/97               N/A
----------------- --------------------------- ---------------------- --------------------------------------------
Australia         50007/97                    2/12/96                EVMS
----------------- --------------------------- ---------------------- --------------------------------------------
Canada            2280412                     2/12/96                EVMS
----------------- --------------------------- ---------------------- --------------------------------------------
EPO               97912942.6                  2/12/96                EVMS
----------------- --------------------------- ---------------------- --------------------------------------------
Japan             520665/98                   2/12/96                EVMS
----------------- --------------------------- ---------------------- --------------------------------------------
Mexico            9904079                     2/12/96                EVMS
----------------- --------------------------- ---------------------- --------------------------------------------
</TABLE>

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00016-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00016-of-00352.parquet"}]]